Title
Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)
Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.
Phase
Phase 3Lead Sponsor
Fundación Lindavista del Corazón ACStudy Type
InterventionalStatus
Terminated Results PostedIndication/Condition
HypertensionIntervention/Treatment
simvastatin ezetimibe valsartan pravastatin ...Study Participants
12Evaluate pleiotropic effects of simvastatin in hypertensive patients.
80 mg valsartan. Duration: 12 months. Tablets
40 mg pravastatin. Duration: 12 months. Tablets
40 mg simvastatin. Duration: 12 months. Tablets
ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
Inclusion Criteria: Females Or Males Over 18 Years Old Patients With Systemic Arterial Hypertension Grade I And II According With The European Society Of Cardiology Left Ventricular hypertrophy Demonstrated By Echocardiography Mild To Moderated hypercholesterolemia Willing To Participate And Sign The Informed Consent Form (ICF) Exclusion Criteria: Type 1 Or 2 Diabetes Mellitus Familiar hypercholesterolemia Low Density Lipoprotein-Cholesterol (LDL-C) > 190 mg/dl History Of Myocardial Infarction Or Stable Chronic Angina Triglycerides >250 mg/dl
| Event Type | Organ System | Event Term |
|---|
Left ventricular hypertrophy reduction was to be measured by echocardiography.
